

# PRESS RELEASE

18 November 2009

## **ENIGMA DIAGNOSTICS SHOWCASES ITS UNIQUE FULLY AUTOMATED rtPCR BASED ML (MINI-LABORATORY) INSTRUMENT FOR POINT-OF- CARE TESTING AT MEDICA 2009 IN DÜSSELDORF, GERMANY**

**Porton Down, UK** – Enigma Diagnostics Limited, the decentralised point-of-care molecular diagnostics company, announces the showcasing of its fully automated Point-of-Care mini-laboratory instrument, the Enigma ML, at MEDICA 2009 at the Düsseldorf Trade Fair Centrehas in Düsseldorf, Germany in Hall 1, stand E07a between 18-20 November.

The Enigma ML offers “Gold Standard” central reference laboratory standards of testing in an instrument developed for decentralised locations. The ML integrates a range of proprietary miniaturised technologies, including the rapid real-time PCR thermocycler and fully automated sample preparation capability, offering the only instrument platform which can deliver true raw sample to result capability in minutes in any location.

Enigma's miniaturised technology provides the paradigm shift necessary to deliver fast, accurate, low cost multi-sample instrument systems for any clinical or applied market testing at point-of-need. The ML is ideally suited for point-of-care and clinical laboratories including hospital clinics and operating rooms doctors' surgeries and pharmacies with extensive test and treat opportunities.

The affordability and ease of use of the ML instrument offers new and first time testing sites to both developed and emerging healthcare economies using previously unavailable PCR-based detection. The ML will be commercially launched in early Q3 2010 for influenza testing following clinical trials and EU/USA regulatory approvals. Further tests will follow in 2010 and 2011.

“The launch of the Enigma ML will provide a paradigm shift in decentralised healthcare testing. We are excited to showcase the Enigma ML at MEDICA which will offer first time use of real-time PCR and next-generation molecular technologies to an array of global users,” said Chairman and CEO John McKinley. “By offering laboratory-standard results in a miniaturised, easy-to-use and cost effective system, we will establish Enigma as the leader of this new global decentralised testing market.”

### **About Enigma Diagnostics Limited**

Enigma Diagnostics Limited is a private UK-based company specializing in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.



# PRESS RELEASE

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

In July 2009, Enigma Diagnostics announced that it signed worldwide licensing and supply agreements with GlaxoSmithKline (GSK). Under the agreements, Enigma will develop the first companion diagnostic influenza tests to identify pandemic & resistant strains of the virus for use on the Enigma ML system.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licences from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit [www.enigmadiagnostics.com](http://www.enigmadiagnostics.com)

## Contacts

### UK Contact:

#### **Enigma Diagnostics**

Deborah Cordingley

[deborah.cordingley@enigmadiagnostics.com](mailto:deborah.cordingley@enigmadiagnostics.com)

+44 1980 590131

### US Contact:

#### **Tiberend Strategic Advisors, Inc.**

212-827-0020

Tamara Bright

[tbright@tiberendstrategicadvisors.com](mailto:tbright@tiberendstrategicadvisors.com)

Chiara DePaolo

[cdepaolo@tiberendstrategicadvisors.com](mailto:cdepaolo@tiberendstrategicadvisors.com)